Key points are not available for this paper at this time.
BACKGROUND: ) in non-NSCLC tumors and report their responsiveness to therapies targeting ALK. MATERIALS AND METHODS: Comprehensive genomic profiling of 114,200 relapsed and metastatic malignancies, including both solid tumors and hematolymphoid cancers, was performed using a hybrid-capture, adaptor ligation-based next-generation sequencing assay. RESULTS: < .0001). CONCLUSION: in clinical trials involving a wider variety of cancer types appears warranted. IMPLICATIONS FOR PRACTICE: fusions irrespective of tumor type or fusions partner.
Ross et al. (Fri,) studied this question.